NNNN — Anbio Biotechnology Balance Sheet
0.000.00%
Last trade - 00:00- $3.72bn
- $3.71bn
- $8.65m
Annual balance sheet for Anbio Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.18 | 8.67 | 9.69 | 11.8 | 11.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.718 | — | 1.88 | 1.06 | 3.66 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.92 | 13.9 | 15.7 | 18.5 | 30.2 |
| Net Property, Plant And Equipment | 0 | 0.012 | 0 | — | — |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 4.92 | 14 | 15.8 | 18.9 | 30.2 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.38 | 1.41 | 0.993 | 1.73 | 0.088 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.38 | 1.41 | 0.993 | 1.73 | 0.088 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2.54 | 12.5 | 14.8 | 17.2 | 30.2 |
| Total Liabilities & Shareholders' Equity | 4.92 | 14 | 15.8 | 18.9 | 30.2 |
| Total Common Shares Outstanding |